Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies
Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver […]